- •Raising glucose quickly is critical in restoring homeostasis and ensuring the well-being of individuals experiencing severe hypoglycemia.
- •Glucagon intramuscular injections have been the standard of care for the treatment of hypoglycemia, but they are difficult for care partners to administer.
- •Glucagon nasal powder offers a relatively new, easy-to-use innovation for treating severe hypoglycemia in those with type 1 or 2 diabetes mellitus.
- •Empirical data suggest glucagon nasal powder is comparable to injectable glucagon regarding its action, half-life, peak, and adverse reactions.
Individuals who take insulin and some oral glucose-lowering agents for type 1 and 2 diabetes mellitus may experience severe hypoglycemia. Glucagon nasal powder offers a relatively new, easy-to-use innovation for treating severe hypoglycemia in those with type 1 or 2 diabetes mellitus. This brief report provides information nurse practitioners can use in prescribing this medication to individuals with diabetes mellitus who are at risk for severe hypoglycemia and in teaching patients and significant others regarding this medication.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The Journal for Nurse Practitioners
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- National Diabetes Statistics Report: coexisting conditions and complications.(2021. Accessed 21 April 2022)
- Professional Practice Committee. 6. Glycemic targets: Standards of Medical Care in Diabetes—2022.Diabetes Care. 2022; 45: S83-S96https://doi.org/10.2337/dc22-S006
- Efficacy and usability of intranasal glucagon for the management of hypoglycemia in patients with diabetes: a systematic review.Clin Ther. 2020; 42: e177-e208https://doi.org/10.1016/j.clinthera.2020.06.024
- Glucagon.https://uspl.lilly.com/glucagon/glucagon.html#pi0Date: 2021Date accessed: May 18, 2022
- GVOKE®.https://www.gvokeglucagon.com/pdf/gvoke-prescribing-information.pdfDate: 2021Date accessed: April 22, 2022
- Inc. ZEGALOGUE—dasiglucagon injection, solution.https://medlibrary.org/lib/rx/meds/zegalogue/Date: 2022Date accessed: April 22, 2022
- Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis.Acta Diabetol. 2020; 57: 743-749https://doi.org/10.1007/s00592-020-01483-y
- Glucagon prescription patterns in patients with either type 1 or 2 diabetes with newly prescribed insulin.Endocr Pract. 2016; 22: 123-135https://doi.org/10.4158/EP15831.OR
- Glucagon prices, coupons and patient assistance programs.https://www.drugs.com/price-guide/glucagonDate: 2022Date accessed: May 24, 2022
- Glucagon.https://www.goodrx.com/glucagonDate: 2022Date accessed: May 24, 2022
- Baqsimi ®-glucagon powder.https://uspl.lilly.com/baqsimi/baqsimi.html#ugDate: 2020Date accessed: April 21, 2022
- Perceptions about glucagon delivery devices for severe hypoglycemia: qualitative research with patients, caregivers, and acquaintances.Clin Ther. 2019; 41: 2073-2089.e.6https://doi.org/10.1016/j.clinthera.2019.08.006
- Glucagon: its evolving role in the management of hypoglycemia.Pharmacotherapy. 2021; 41: 623-633https://doi.org/10.1002/phar.2534
- Drugs.com. Baqsimi prices, coupons and patient assistance programs.https://www.drugs.com/price-guide/baqsimiDate: 2022Date accessed: May 26, 2022
- T1D Exchange Intranasal Glucagon Investigators. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes.Diabetes Care. 2016; 39: 555-562https://doi.org/10.2337/dc15-1606
- Glucagon therapy: a comparison of current and novel treatments.Diabetes Spectr. 2020; 33: 347-351https://doi.org/10.2337/ds19-0076
Joan S. Grant, PhD, RN, is a professor at the University of Alabama at Birmingham School of Nursing, Birmingham, AL, and can be contacted at [email protected]
Michele, H. Talley, PhD, ACNP-BC, is an associate professor at the University of Alabama at Birmingham School of Nursing, Birmingham, AL.
Published online: August 31, 2022
Publication stageIn Press Corrected Proof
In compliance with standard ethical guidelines, the authors report no relationships with business or industry that would pose a conflict of interest.
Published by Elsevier Inc.